NewAmsterdam Pharma reported cash from operations of -$39.21M and free cash flow of -$39.29M for the quarter ended Jun 2026, down 4.1% year over year. This cash flow statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Net Income | -42.02M | -38.29M | -47.13M | -49.47M | -93.77M | -39.01M | -16.65M | -92.18M | -39.53M | -17.36M | -72.00M | -74.92M | -48.44M | -64.14M | |
| Share-based Compensation | 11.37M | 7.62M | 5.56M | 5.39M | 6.01M | 19.33M | 19.78M | 20.18M | 9.41M | 21.85M | 22.20M | 21.77M | 14.02M | 20.88M | 19.87M |
| Cash from Operations | -31.86M | -29.30M | -46.98M | -33.07M | -54.60M | -53.98M | -12.50M | -37.48M | -36.47M | -37.67M | -32.77M | -40.88M | -30.60M | -39.21M | |
| Depreciation, Depletion & Amortization | |||||||||||||||
| Amortization of Deferred Charges | -0.51M | -0.47M | -0.40M | -0.02M | 0.01M | -0.05M | |||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.01M | 0.01M | 0.01M | 0.01M | 0.02M | 0.03M | 0.05M | 0.05M | 0.04M | 0.06M | 0.06M | 0.06M | 0.06M | ||
| Change in Working Capital | |||||||||||||||
| Change in Account Payables | -2.92M | 4.33M | -9.23M | 12.89M | -8.31M | -3.35M | 1.91M | -3.20M | 2.25M | -0.39M | -2.27M | 5.32M | -0.79M | -2.69M | |
| Change in Accured Expenses | 7.00M | -5.07M | 9.34M | -5.80M | -1.38M | 0.27M | 0.40M | 2.39M | -4.95M | 1.44M | 0.64M | 5.32M | -10.33M | 5.18M | |
| Other Working Capital Changes | -3.24M | -1.72M | -2.94M | -0.80M | -1.40M | -2.28M | -1.79M | 1.51M | -2.98M | -3.03M | 3.99M | ||||
| Investing Activities | |||||||||||||||
| Capital Expenditures | 0.01M | 0.01M | 0.01M | 0.00M | 0.39M | 0.21M | 0.07M | 0.00M | 0.02M | 0.09M | 0.04M | 0.10M | 0.04M | 0.08M | |
| Change in Acquisitions & Divestments | 12.50M | 24.66M | 34.40M | 50.50M | 51.00M | 46.50M | |||||||||
| Cash from Investing Activities | -0.01M | -0.01M | -0.01M | -0.00M | -0.39M | -0.21M | -0.07M | -62.18M | 2.85M | -159.14M | 2.51M | -21.14M | -11.51M | -4.76M | |
| Financing Activities | |||||||||||||||
| Other financing activities | 2.39M | 6.23M | 0.00M | 8.76M | 4.66M | 0.34M | 7.92M | 3.42M | 5.62M | 12.50M | 10.41M | 10.89M | |||
| Change in Capital Stock | |||||||||||||||
| Net Shares Issued and Repurchased | 6.83M | 4.10M | 5.28M | 3.73M | 4.79M | 2.27M | |||||||||
| Misc. | |||||||||||||||
| Cash from Financing Activities | 2.39M | 6.33M | 0.19M | 198.18M | 4.66M | 0.06M | 456.61M | 6.52M | 3.42M | 5.89M | 13.68M | 11.06M | 11.04M | ||
| Exchange Rate Effect | 3.06M | -1.63M | -1.60M | 5.22M | -2.50M | -0.91M | 4.54M | -7.94M | 3.77M | 8.83M | 0.22M | -0.06M | -1.33M | -0.50M | |
| Change in Cash | -29.48M | -22.98M | -46.80M | -33.08M | 143.19M | -49.53M | -12.52M | 356.95M | -27.09M | -193.38M | -24.37M | -48.33M | -31.05M | -32.94M | |
| Free Cash Flow | -31.87M | -29.31M | -46.98M | -33.08M | -54.99M | -54.19M | -12.58M | -37.48M | -36.48M | -37.76M | -32.81M | -40.98M | -30.64M | -39.29M | |
| Net Cash Flow | -29.48M | -22.98M | -46.80M | -33.08M | 143.19M | -49.53M | -12.52M | 356.95M | -27.09M | -193.38M | -24.37M | -48.33M | -31.05M | -32.94M |